2-(2H-1,3-Benzodioxol-5-YL)-4,4-dimethyl-6-phenyl-1H,4H,5H,6H-imidazo[4,5-E]indazole

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 2-(2H-1,3-Benzodioxol-5-YL)-4,4-dimethyl-6-phenyl-1H,4H,5H,6H-imidazo[4,5-E]indazole
• 英文别名: 2-(1,3-benzodioxol-5-yl)-4,4-dimethyl-6-phenyl-3,5-dihydroimidazo[4,5-e]indazole
• 化学式: C₂₃H₂₀N₄O₂
• mdl: MFCD05257958
• 分子量: 384.4
• InChiKey: YZPBVSCVZRAXQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  29
• 可旋转键数：
  2
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  65
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• LANTHIONINE SYNTHETASE COMPONENT C-LIKE PROTEINS AS MOLECULAR TARGETS FOR PREVENTING AND TREATING DISEASES AND DISORDERS
  申请人：BASSAGANYA-RIERA JOSEP

  公开号：US20150241448A1

  公开（公告）日：2015-08-27

  The present invention relates to the field of medical treatments for diseases and disorders. More specifically, the present invention relates to the use of the lanthionine synthetase component C-like (LANCL) proteins as therapeutic targets for novel classes of anti-inflammatory, immune regulatory and antidiabetic drugs. This includes but it is not limited to abscisic acid (ABA), ABA analogs, benzimidazophenyls, repurposed drugs or drug combinations, including thiazolidinediones (TZDs); naturally occurring compounds such as conjugated diene fatty acids, conjugated triene fatty acids, isoprenoids, and natural and synthetic agonists of peroxisome proliferator-activated receptors that activate this receptor through an alternative mechanism of action involving LANCL2 or other membrane proteins to treat or prevent the common inflammatory pathogenesis underlying type 2 diabetes, atherosclerosis, cancer, some inflammatory infectious diseases such as influenza and autoimmune diseases including but not limited to inflammatory bowel disease (Crohn's disease and Ulcerative colitis), rheumatoid arthritis, multiple sclerosis and type 1 diabetes and other chronic inflammatory conditions.
• US9101573B2
  申请人：——

  公开号：US9101573B2

  公开（公告）日：2015-08-11